{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zeng L"],"funding":["NCATS NIH HHS","NIA NIH HHS","National Institute on Aging"],"pagination":["e6108"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11265565"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["39(6)"],"pubmed_abstract":["<h4>Objectives</h4>To examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia.<h4>Methods</h4>The Apathy in Dementia Methylphenidate Trial 2 (ADMET2) trial was a multicenter randomized, placebo-controlled trial of MPH to treat apathy in individuals with apathy and AD. Participants in ADMET2 had vital signs and weight measured at monthly visits through 6 months. AEs, including insomnia, falls, and cardiovascular events, were reported at every visit by participants and families using a symptom checklist.<h4>Results</h4>The study included 98 participants in the MPH group and 101 in the placebo group. Participants in the MPH group experienced g"],"journal":["International journal of geriatric psychiatry"],"pubmed_title":["Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)."],"pmcid":["PMC11265565"],"funding_grant_id":["U01 AG061357","P30 AG066511","UL1 TR001863","R01 AG055132","U54 AG065187","P30 AG066507","P30 AG072947","R01 AG046543"],"pubmed_authors":["Lerner AJ","Brawman-Mintzer O","Herrmann N","Craft S","Zeng L","Gross AL","Perin J","Shade D","Levey A","Padala PR","Mintzer JE","van Dyck CH","Rosenberg PB","Lanctot KL","Porsteinsson AP"],"additional_accession":[]},"is_claimable":false,"name":"Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).","description":"<h4>Objectives</h4>To examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia.<h4>Methods</h4>The Apathy in Dementia Methylphenidate Trial 2 (ADMET2) trial was a multicenter randomized, placebo-controlled trial of MPH to treat apathy in individuals with apathy and AD. Participants in ADMET2 had vital signs and weight measured at monthly visits through 6 months. AEs, including insomnia, falls, and cardiovascular events, were reported at every visit by participants and families using a symptom checklist.<h4>Results</h4>The study included 98 participants in the MPH group and 101 in the placebo group. Participants in the MPH group experienced g","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-06-01T16:07:24.018Z","creation":"2026-04-08T13:59:19.951Z"},"accession":"S-EPMC11265565","cross_references":{"pubmed":["38858522"],"doi":["10.1002/gps.6108"]}}